US-based clinical-stage microbiome firm Rebiotix has started patient enrolment in a Phase III clinical trial of RBX2660 to prevent recurrent Clostridium difficile (C. diff) infection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

RBX2660 is developed using the firm’s Microbiota Restoration Therapy (MRT) platform, which is a stabilised drug technology that delivers spore and non-spore forming microbes into patient’s intestinal tract to restore healthier state of a dysbiotic gut.

The randomised, double-blind, multi-centre, placebo-controlled Phase III trial is designed to investigate the efficacy and safety of RBX2660 at clinical sites in the US and Canada.

While the trial’s primary endpoint is the proportion of subjects with treatment success after a blinded RBX2660 therapy, the treatment success will act as prevention of recurrent infection for eight weeks.

"Initiating the Phase III clinical study of RBX2660 is a significant milestone for Rebiotix and showcases the potential of our MRT platform to enable the development of microbiome-directed drug products."

Rebiotix president and CEO Lee Jones said: “We plan to continue our strong momentum generated by our Phase II results in this Phase III trial as we seek to advance RBX2660 toward registration and potential approval so patients have an option for this unmet medical need.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Initiating the Phase III clinical study of RBX2660 is a significant milestone for Rebiotix and showcases the potential of our MRT platform to enable the development of microbiome-directed drug products.”

RBX2660’s Phase II programme for the prevention of C. diff infection included three separate Phase II trials, one of which was conducted as a randomised, double-blind, placebo controlled Phase IIb study.

The RBX2660 is reported to have been evaluated in up to 300 subjects to date, with a 24-month follow-up following treatment.

Image: Clostridium difficile bacteria. Photo: courtesy of Janice Carr/CDC.